Anthracyclines

What it is

Anthracyclines are chemotherapy drugs, first identified in the 1950s, used for many cancers but limited by dose-related heart toxicity. They are a class of anti-cancer medicines used in blood cancers and solid tumours, including breast cancer, lymphomas, leukaemias, sarcomas, and some paediatric cancers. A key practical fact is that the risk of cardiotoxicity rises as the cumulative lifetime dose increases, especially with doxorubicin.

Common anthracyclines include:

Drug	Common use examples
Doxorubicin	Breast cancer, lymphoma, sarcoma, many combination regimens
Daunorubicin	Leukemias
Epirubicin	Breast cancer and other solid tumours
Idarubicin	Acute leukaemias
Anthracyclines are among the most effective cancer drugs in routine oncology, but they are also one of the best-known causes of chemotherapy-related heart damage. In practice, oncologists balance their anti-cancer benefit against risks such as reduced heart pumping function, low blood counts, mouth sores, nausea, hair loss, and tissue injury if the drug leaks outside the vein. In India, these medicines are widely used in tertiary cancer centres and government hospitals because they are part of many standard regimens and are available as generics.

How it works

Anthracyclines damage cancer cells mainly by interfering with DNA and enzymes needed for cell division. They can intercalate into DNA, inhibit topoisomerase II, and generate oxidative stress. These effects make it harder for rapidly dividing cancer cells to survive and replicate.

The same mechanisms also explain some toxicities. Heart muscle cells appear especially vulnerable to anthracycline injury because of oxidative stress, mitochondrial damage, and effects on topoisomerase II beta in cardiac tissue. This is why anthracycline cardiotoxicity can appear during treatment, soon after treatment, or years later.

Anthracyclines are usually given intravenously in cycles, often with other drugs. The exact schedule depends on the cancer type and protocol. Some formulations, such as liposomal doxorubicin, were developed to change drug distribution in the body and may reduce some toxicities in selected settings.

Evidence and uses

Anthracyclines have a long record of benefit across multiple cancers and remain part of standard treatment in many guidelines. They are used with curative intent in some lymphomas and leukaemias, as part of adjuvant or neoadjuvant treatment in some breast cancers, and in palliative treatment for certain advanced cancers.

Examples of where they are commonly used include:

1. Breast cancer: often in combination regimens such as doxorubicin or epirubicin-based protocols.
2. Lymphoma: doxorubicin is a core drug in CHOP-like regimens.
3. Leukaemia: daunorubicin and idarubicin are used in induction regimens for acute leukaemias.
4. Sarcoma and paediatric cancers: doxorubicin remains important in several protocols.

Their main limitation is toxicity, especially to the heart. Reviews of anthracycline cardiotoxicity describe a clear dose-response relationship, with higher cumulative exposure linked to higher risk of left ventricular dysfunction and heart failure. Risk is also affected by age, prior chest radiation, existing heart disease, hypertension, and use of other potentially cardiotoxic cancer drugs such as trastuzumab.

Because of this, some patients receive preventive strategies such as lower cumulative doses, slower infusion schedules, liposomal formulations, or dexrazoxane in selected cases. These decisions are individualised by the oncology team.

Safety and interactions

The most important safety issue is cardiotoxicity. This can range from an asymptomatic drop in left ventricular ejection fraction to symptomatic heart failure. The risk is not the same for every patient, but it generally increases with higher cumulative dose and with other cardiac risk factors.

Other important adverse effects include:

Safety issue	Why it matters
Low blood counts	Can raise infection and bleeding risk
Nausea and vomiting	Often preventable with antiemetic medicines
Mouth sores	Can affect eating and hydration
Hair loss	Common with several anthracyclines
Extravasation	Leakage outside the vein can cause severe local tissue injury
Secondary leukaemia	Rare but recognised long-term risk

Anthracyclines can interact clinically with other treatments that stress the heart or bone marrow. Examples include trastuzumab, some targeted therapies, prior mediastinal radiation, and other myelosuppressive chemotherapy. Patients should tell their oncology team about all prescription drugs, over-the-counter medicines, and supplements. Herbal products and antioxidants are sometimes used during chemotherapy, but evidence for benefit is limited and some may interfere with treatment plans or supportive medicines. Do not start supplements or Ayurvedic products during chemotherapy without checking with the treating oncologist or oncology pharmacist.

Anthracyclines are vesicants, so careful IV administration is essential. If pain, burning, swelling, or redness occurs at the infusion site, staff should be told immediately.

When to see a clinician

Contact your cancer team urgently if you develop fever, chills, shortness of breath, chest pain, new palpitations, fainting, severe vomiting, inability to drink fluids, or redness and pain around the IV site. During or after anthracycline treatment, symptoms such as breathlessness on exertion, ankle swelling, unexplained fatigue, or needing extra pillows to sleep can suggest heart problems and should not be ignored.

Patients with diabetes, hypertension, prior heart disease, prior chest radiation, or older age may need closer monitoring. In many centres, this includes baseline and follow-up echocardiography, and sometimes cardiac biomarkers such as troponin or natriuretic peptides. If you are being treated in India and have records from another hospital, bring prior chemotherapy summaries so the team can calculate your cumulative anthracycline exposure accurately.

Limitations and open questions

Anthracyclines are highly effective, but predicting exactly who will develop cardiotoxicity remains imperfect. Not every patient with a high cumulative dose develops heart failure, and some patients develop cardiac dysfunction at lower doses. Research is ongoing on genetic susceptibility, better biomarkers, and imaging methods that can detect injury earlier than standard ejection fraction measurements.

There are also open questions about the best prevention strategy in different cancers and age groups. Liposomal formulations and dexrazoxane can reduce risk in some settings, but they are not used for every patient. Evidence continues to evolve on how best to balance cancer control with long-term heart safety, especially as more patients live many years after treatment.

For patients and families, the practical point is that anthracyclines are established and often very useful cancer drugs, but they require planned monitoring and prompt reporting of symptoms. Decisions about using them should be made with an oncologist who can weigh expected benefit, cumulative dose, and individual heart risk.